Recently, the official acceptance notifications for the 44th Annual Meeting of The Obesity Society, Obesity Week® 2026, have been released. Leveraging AlfaBodY, the intelligent molecular design platform, two research achievements from Great Bay Bio developed in collaboration with partners to advance innovative therapeutics for weight management have been accepted. The team is invited to deliver an on-site oral presentation and present a poster.

▲ Two research projects powered by Great Bay Bio’s intelligent molecular design platform AlfaBodY have been selected for Obesity Week® 2026

Oral Presentation: AlfaBodY Enables GIPR Antibodies for Sustained Weight Loss

At the invitation of the conference, Michael Chen, Ph.D., Co-Founder & CEO of Great Bay Bio, will deliver an on-site presentation titled Generation of GIPR Antagonist Antibodies With Sustained Weight Loss in DIO Mice by AlfaBodY.

Research data verifies that GIPR antagonist antibodies developed via the AlfaBodY platform exhibit durable and stable weight-lowering effects in diet-induced obese (DIO) mouse models. The work delivers novel candidate molecules and innovative strategies for the development of next-generation therapeutic antibodies against obesity.

▲ The research on AlfaBodY-enabled GIPR antibodies for sustained weight loss is available on bioRxiv, the international preprint platform for biomedical research

Poster Presentation: AlfaBodY Enables ActRIIA/B Antibodies for Fat Loss While Preserving Muscle Mass

Great Bay Bio’s poster is titled AlfaBodY-Derived ActRIIA/B Antibody With Semaglutide Enhances Fat Loss and Lean Mass in DIO Mice.

This study investigates the combination regimen of an ActRIIA/B antibody and semaglutide. Experimental data demonstrates strong synergistic effects between the two agents, effectively reducing body fat and increasing lean mass. The combination holds promise to address a key industry challenge of muscle loss associated with current weight-loss therapies, enabling high-quality weight loss characterized by fat reduction without muscle wasting, and opening new avenues for innovative combination therapies with GLP‑1 agents.

▲ The research on AlfaBodY-enabled ActRIIA/B antibodies for fat loss and muscle preservation is available on bioRxiv, the international preprint platform for biomedical research

The conference will take place November 14–17, 2026, in Washington, D.C., USA. It brings together thousands of researchers, clinicians and industry professionals worldwide engaged in obesity research to showcase cutting-edge advances in obesity mechanism studies and innovative drug development.

The selection of these two studies for the prestigious international academic stage of Obesity Week fully validates Great Bay Bio’s strengths in AI-driven antibody innovation, earning wide recognition from the global obesity research community.

Supported by a comprehensive AI-powered R&D ecosystem, Great Bay Bio continuously empowers end-to-end development of global biologic drugs from target discovery to preclinical delivery, offering one-stop R&D services including antibody design, molecular evaluation, sequence optimization, cell line construction and commercial cell culture medium supply.

Backed by technical strengths featuring speed, high productivity and predictability, Great Bay Bio supports partners in tackling difficult-to-drug targets such as GIPR and ActRII, streamlines bioprocess development, shortens R&D timelines and reduces trial-and-error costs for projects.